Links from this page to related variants, conditions, drugs and topics are not included for automated readers. Those connections are the Gene Knowledge Graph and are licensed as data: https://www.mygenelog.com/license
APOE · rs7412
Stands on its own. Nothing else here links to this position yet — but the page above is the point: what the research found, what each genotype means, and where it came from, in language you can read. Links to conditions, drugs and the senses appear automatically if we write them.
Strength of the evidence
Its strongest genetic-study result is p = 10−2868, with 1,006 associations in the GWAS Catalog.
4: ClinVar disease-causing, reviewed by an expert panel or a guideline (3–4 stars). 3: ClinVar, several labs agreeing (2 stars), or a genetic study at p ≤ 10−50. 2: ClinVar from one lab (1 star), or p ≤ 10−20. 1: ClinVar submitted without criteria (0 stars), or genome-wide significance (p ≤ 5×10−8). The higher of the two counts. It says how solid the evidence is, not whether it matters for a particular person.
What ClinVar records
Classification
drug response for Familial type 3 hyperlipoproteinemia, atorvastatin response - Efficacy, Warfarin response, Hypercholesterolemia; reviewed by expert panel (3 of 4 stars, 12 submitters), last evaluated 2021-03-24.
ClinVar record 17848 NM_000041.2(APOE):c.526C>T (p.Arg176Cys)
Change history MyGeneLog™ keeps a copy of every weekly release from 2026-10-19 and compares them. This position's classification has not changed since.
What this is ClinVar's aggregate record for this position (as of its 2026-11-01 release), not a result about you. A classification describes the variant against the condition named, as laboratories submitted it. Whether a person carries this variant, and what that would mean for them, is a question for a clinical test and a genetic counsellor.
How common each version is
CT
C 93.1% · T 6.9%
C 93.8% · T 6.2%
C 95.6% · T 4.4%
C 92.2% · T 7.8%
C 92.5% · T 7.5%
C 92.2% · T 7.8%
By ancestry gnomAD
C 92.0% · T 8.0%
C 92.1% · T 7.9%
C 89.5% · T 10.4%
C 96.3% · T 3.7%
C 95.8% · T 4.2%
C 95.2% · T 4.8%
C 95.8% · T 4.2%
C 93.0% · T 6.9%
The share of all copies of this position that are each version. Source: the population studies published in dbSNP (US NCBI); each row names its study. The ancestry rows are gnomAD's own groups (via Ensembl), as the survey defines them, not races.
2026-08-31 · medicalxpress.com, reporting on Washington University in St. Louis (Belloy et al.)
Scientists identify genes that could reduce APOE4 Alzheimer's disease risk
Directly about APOE4 carriers, this page's own genotype (rs429358/rs7412). Not a treatment yet -- early-stage genomic analysis identifying drug targets, not a drug approval or trial result -- flagged as such on the page.
2026-07-14 · Eisai / Biogen (FDA supplemental approval)
Direct follow-on to this session's own apoe4-testing-before-alzheimers-drugs blog post -- APOE4 genotype-stratified ARIA risk is why pre-treatment genotyping matters, and this news is a real regulatory change to how lecanemab treatment starts. No usable thumbnail found after multiple source fetch attempts (403/paywall/empty on Eisai, Biogen, NeurologyLive, AJMC, Medscape, alzimpact.org) -- this is the first real test of the site-favicon fallback added the same day.
Licensed CC BY-NC 4.0: free to read, share and adapt for non-commercial use, naming MyGeneLog™ and linking the exact page. Commercial use, including training or serving a commercial AI system, needs a licence — https://www.mygenelog.com/license
Cholesterol, total (rs7412). MyGeneLog™. https://www.mygenelog.com/variants/rs7412